If you have been reading about GHRH analog and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-06-16. Numbers and descriptions here follow the published literature rather than marketing material.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH receptor agonist |
| Residue count | 44 amino acids | Matches human GHRH(1-44) length |
| N-terminal modification | trans-3-hexenoyl group | Confers resistance to dipeptidyl peptidase IV |
| Appearance | White to off-white powder | Typically supplied lyophilized in a sealed vial |
| Solubility class | Freely soluble in water | Hydrophilic peptide; polar solvent compatible |
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
稳定性研究通常考察温度、光照、湿度和 pH 对肽链的影响。冻干粉在低温避光条件下较为稳定，复溶后则需控制保存时间并避免反复冻融。肽类可能发生氧化、脱酰胺、水解和聚集，这些变化会改变色谱纯度。强制降解实验用于识别主要降解途径并验证分析方法的专属性。
质量控制项目一般包括外观、身份、纯度、含量、有关物质、水分和微生物限度。身份确认可通过肽图谱、氨基酸分析和质谱完成，纯度则用面积归一化法计算。研究级材料与药品级材料的要求不同，前者常缺少完整药典验证。不同批次间杂质谱是否影响活性，仍是一个需要具体数据回答的问题。
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
=== Synthesis === Trimebutine can be synthesised from 1-phenylpropan-1-one (1). Firstly, it is converted to the corresponding oxirane through trimethylsulfoxonium idoide with sodium hydride in DMSO and THF, yielding 2-ethyl-2-phenyl-oxirane (2). Next, 2 undergoes ring-opening with dimethylaluminium N,N-dimethylamide in diethyl ether, yielding 2-(dimethylamino)-2-phenyl-butan-1-ol (4) and 2-phenylbutanal (3) as a byproduct. Then, 4 reacts with 3,4,5-trimethoxybenzoyl chloride (5) in triethylamine and THF, which is catalysed by 4-dimethylaminopyrridine (DMAP), yielding trimebutine.
where U is the elastic energy of the system and a is the crack length. Either the load P or the displacement u are constant while evaluating the above expressions. Irwin showed that for a mode I crack (opening mode) the strain energy release rate and the stress intensity factor are related by:
== Epidemiology == Fibromyalgia is estimated to affect 1.8% of the population. German Federal Ministry of Health guidance is that about 2% of adults in Germany suffer from fibromyalgia. Information about FM prevalence in many parts of the world is limited by lack of information and by differing diagnosis standards. A 2024 study found more patients met fibromyalgia proxy criteria than were clinically diagnosed with fibromyalgia, implying that fibromyalgia is underdiagnosed. Historically, diagnosed FM cases have been between 4%-20% male. As a result historically most FM research has focused on women. There has been debate about whether men experience differences in FM symptoms compared to women. Men may be relatively underdiagnosed, perhaps because they interact with medical services over chronic pain less than women do. The genetic architecture of fibromyalgia is nearly identical between males and females.
Sources: en.wikipedia.org
=== Deep learning reconstruction === Deep learning approaches extend traditional acceleration methods by training neural networks on large datasets of paired undersampled and fully-sampled MRI scans, enabling image reconstruction at higher acceleration factors than classical parallel imaging alone. Rather than relying on hand-crafted sparsity priors as in compressed sensing, these models learn reconstruction directly from data. One prominent approach, the end-to-end variational network (E2E-VarNet), combines sensitivity map estimation and iterative refinement in a fully learned pipeline, achieving state-of-the-art reconstruction quality on the fastMRI benchmark for both knee and brain MRI.. The fastMRI initiative, a collaboration between Meta AI Research (FAIR) and NYU Langone Health, established the field's primary open benchmark by releasing over 1.5 million raw MRI measurements from knee, brain, and prostate scans in 2018. Annual fastMRI challenges have benchmarked reconstruction quality across international research teams. A clinical interchangeability study confirmed that deep learning reconstruction at 4× acceleration produces images diagnostically equivalent to fully-sampled acquisitions for knee imaging at 3T, and these methods have since been adopted clinically at major medical centers.
Economically, Southern Rhodesia developed an economy that was narrowly based on the production of a few primary products, notably, chromium and tobacco. It was therefore vulnerable to the economic cycle. The deep recession of the 1930s gave way to a post-war boom. This boom prompted the immigration of about 200,000 whites between 1945 and 1970, taking the white population up to 307,000. A large number of these immigrants were of British working-class origin, with others coming from the Belgian Congo, Kenya, Tanzania, and later Angola and Mozambique. They established a relatively balanced economy, transforming what was once a primary producer dependent on backwoods farming into an modest industrial power which spawned a strong manufacturing sector, iron and steel industries, and modern mining ventures. These economic successes owed a lot to the immigration of skilled labour and backing from South Africa. The economy of the state of Rhodesia sustained international sanctions for a decade following the declaration of its independence, a resistance which waned as more southern African states declared independence and majority rule as well as the destruction caused by the Rhodesian Bush War.
Spatial and temporal control of substrate labeling has been investigated using photoactivatable cyclooctynes. This allows equilibration of the alkyne prior to reaction in order to reduce artifacts as a result of concentration gradients. Masked cyclooctynes are unable to react with azides in the dark but become reactive alkynes upon irradiation with light.
Sources: en.wikipedia.org
The principal difference is a chemical cap on the N-terminal tyrosine that prevents rapid enzymatic cleavage. Native GHRH is degraded within minutes in plasma, whereas the modified peptide persists considerably longer. The amino acid backbone otherwise mirrors the natural hormone.
No. It is a receptor agonist that stimulates the pituitary to release endogenous growth hormone. It does not contain or deliver growth hormone. Its downstream effects therefore depend on a functioning pituitary and an intact signaling pathway.
Pituitary responsiveness, receptor availability, and the natural pulsatility of the growth hormone axis all contribute. Because the compound amplifies an existing release pattern rather than overriding it, timing and physiological state matter. Individual variability in response is well documented but not fully explained.
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Binding stimulates cyclic AMP signaling and growth hormone secretion. This is the same receptor used by endogenous GHRH.